Xponance Inc. Has $1.29 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Xponance Inc. grew its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.4% in the first quarter, HoldingsChannel reports. The fund owned 45,412 shares of the company’s stock after acquiring an additional 642 shares during the period. Xponance Inc.’s holdings in Moderna were worth $1,287,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Financial Gravity Asset Management Inc. acquired a new position in Moderna during the 1st quarter worth approximately $1,278,000. Nisa Investment Advisors LLC boosted its position in Moderna by 166.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 34,108 shares of the company’s stock worth $967,000 after acquiring an additional 21,330 shares during the last quarter. Moloney Securities Asset Management LLC boosted its position in Moderna by 933.2% during the 1st quarter. Moloney Securities Asset Management LLC now owns 50,150 shares of the company’s stock worth $1,422,000 after acquiring an additional 45,296 shares during the last quarter. New Insight Wealth Advisors boosted its position in Moderna by 17.3% during the 1st quarter. New Insight Wealth Advisors now owns 10,023 shares of the company’s stock worth $284,000 after acquiring an additional 1,478 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in Moderna by 0.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 221,718 shares of the company’s stock worth $6,060,000 after acquiring an additional 1,473 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 3.9%

MRNA opened at $31.58 on Wednesday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $127.20. The stock’s fifty day simple moving average is $27.46 and its 200 day simple moving average is $31.04. The stock has a market cap of $12.21 billion, a PE ratio of -3.62 and a beta of 1.84.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The business had revenue of $108.00 million for the quarter, compared to analysts’ expectations of $130.35 million. During the same quarter in the prior year, the business earned ($3.07) EPS. The firm’s revenue for the quarter was down 35.3% on a year-over-year basis. Equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on MRNA shares. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. Evercore ISI reduced their price target on Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research report on Sunday. Royal Bank Of Canada cut their price objective on Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a report on Friday, May 2nd. Finally, Cowen started coverage on Moderna in a report on Sunday. They issued a “hold” rating for the company. Four equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $46.61.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.